AQR Capital Management LLC acquired a new stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 636,136 shares of the company's stock, valued at approximately $872,000. AQR Capital Management LLC owned about 1.32% of BioAtla at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD bought a new position in BioAtla during the 1st quarter worth approximately $45,000. Acadian Asset Management LLC grew its holdings in shares of BioAtla by 57.6% in the 1st quarter. Acadian Asset Management LLC now owns 155,188 shares of the company's stock valued at $532,000 after buying an additional 56,748 shares during the period. Virtu Financial LLC bought a new stake in shares of BioAtla in the 1st quarter valued at $103,000. Vanguard Group Inc. raised its stake in BioAtla by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company's stock worth $7,221,000 after buying an additional 17,667 shares during the period. Finally, PVG Asset Management Corp bought a new position in BioAtla during the fourth quarter worth about $161,000. Institutional investors and hedge funds own 77.23% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, JMP Securities restated a "market outperform" rating and issued a $5.00 price target on shares of BioAtla in a report on Monday, September 16th.
Get Our Latest Stock Analysis on BioAtla
BioAtla Price Performance
BCAB stock traded up $0.14 during mid-day trading on Friday, reaching $2.07. The company had a trading volume of 828,753 shares, compared to its average volume of 835,896. The company has a market capitalization of $100.06 million, a price-to-earnings ratio of -0.95 and a beta of 1.06. BioAtla, Inc. has a 52 week low of $1.14 and a 52 week high of $4.02. The stock has a 50 day simple moving average of $1.78 and a two-hundred day simple moving average of $2.04.
BioAtla (NASDAQ:BCAB - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. During the same quarter in the prior year, the firm earned ($0.75) earnings per share. On average, equities analysts predict that BioAtla, Inc. will post -1.52 EPS for the current year.
BioAtla Company Profile
(
Free Report)
BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
See Also
Before you consider BioAtla, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioAtla wasn't on the list.
While BioAtla currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.